Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Patrick W. Serruys; Pim de Feyter; Carlos Macaya; N. Kokott; Jean‐Luc Puel; Matthias Vrolix; Angelo Branzi; Marcelo Chiara Bertolami; Graham Jackson; Bradley H. Strauss; Bernhard Meier

Related publications

Article2003

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Pedro A. Lemos, G. Boxho, Dick Goedhart, Brian J. O’Neil, J. P. Broustet, Gunnar H. Berghoefer, C. Alonso, A. Boehmer, Pim de Feyter, Patrick W. Serruys

Journal of the American College of Cardiology

Article2005

Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention

Thomas E. Delea, Terry A. Jacobson, Patrick W. Serruys, John Edelsberg, Gerry Oster

Annals of Pharmacotherapy

Article2002

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Patrick W. Serruys

JAMA

Article2023

Quantitative flow ratio for the prediction of coronary events after percutaneous coronary intervention

Shigetaka Kageyama, Neil O’Leary, Pruthvi Chenniganahosahalli Revaiah, Kai Ninomiya, Shinichiro Masuda, Nozomi Kotoku, Nidhi Ilancheran, Scot Garg, Emma Harte, Gráinne Ní Bheoláin, Johan H. C. Reiber, Shengxian Tu, Azfar Zaman, Manel Sabaté, Helge Möllmann, Faisal Sharif, Julien Lemoine, Adrian Włodarczak, Yoshinobu Onuma, Patrick W. Serruys, On Behalf Of The Multivessel Talent Trial Investigators

EuroIntervention

Letter2021

Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?

Mattia Lunardi, Yoshinobu Onuma, Patrick W. Serruys

European Heart Journal

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Abstract

Discussion(0)

Related publications

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Quantitative flow ratio for the prediction of coronary events after percutaneous coronary intervention

Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Abstract

Discussion(0)

Related publications

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;

Quantitative flow ratio for the prediction of coronary events after percutaneous coronary intervention

Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>